Click HERE to register.

Join John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci, Nicole Lamanna, MD, and Philip A. Thompson, MB, MS, for PeerView's “Seminars and Tumor Board” live web broadcast which will pair compelling, real-world case scenarios with the practice-changing evidence that continues to support the increasing role in treatment for novel therapeutics in CLL. This event will also explore the future of CLL care and illustrate how novel combinations and cellular therapy may lead to deep, durable, and minimal residual disease-negative responses. Throughout, our expert panel will describe the challenges and milestones of the patient’s journey in order to illustrate the human face of the dramatic progress made in managing CLL in recent years. Register now to join the experts for this unique activity and learn how innovation is fueling changes in treatment for CLL.

Activity Description

The validation of innovative therapeutics for the treatment of chronic lymphocytic leukemia (CLL) has radically upended a decades-long consensus centered on chemotherapy-based treatment and provided clinicians and patients with a wide range of personalized treatment options. These highly active therapies, including BTK, PI3K, and BCL-2 inhibitors and next-generation antibodies, have opened the door to “uncharted medical territory,” where potent treatment, modern safety management strategies, and the potential for long-lasting, robust responses are redefining the approach to caring for CLL patients.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematologist-oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naive or relapsed/refractory CLL
• Summarize current safety and efficacy evidence and practice guideline recommendations related to the use of novel therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies across the spectrum of CLL
• Select personalized initial or sequential treatment regimens with novel components for patients with treatment-naive or relapsed CLL
• Manage the unique spectrum of adverse events associated with the use of novel therapies in patients with CLL
• Educate patients with CLL about treatment expectations, unique toxicity profiles, and dosing/adherence considerations with novel therapeutics

Faculty

Chair & Presenter

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Health NHS Trust
Barts and The London School of Medicine, Queen Mary University of London
London, England, United Kingdom

Presenters

Ryan Jacobs, MD
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina

Alessandra Tedeschi, MD
Niguarda Cancer Center
Niguarda Hospital
Milano, Italy

Philip A. Thompson, MB, MS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Patient Advocate

Terry Evans
CLL Patient & Advocate
Huntington Beach, California

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Accreditation

The Penn State College of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.